(1 - 21 from 27
)
Mole…n Announces Agreement to Produce WP1122 for Expanded ...edition.cnn.com › business › newsfeeds › prnewswire
edition.cnn.com
Jul 15, · ... to make sure we had a reliable source of drug supply located here in the US," commented Walter Klemp, Chairman and CEO of Mole…n.
Breakthrough: WP1066 inhibits PD-L1 as well as STAT3www.drugdiscoverynews.com › breakthrough-wp1066-inhibits-pd-l1-as-w...
www.drugdiscoverynews.com
Jan 14, · Added Walter Klemp, Mole…n's chairman and CEO: “This potential was initially reported in a Japanese study (Journal of Clinical and ...
Biotech Resurgent Growth Championed by Cancer Research and Clinical...
www.prnewswire.co.uk
... to treat additional patients with AML and to generate positive clinical data regarding Annamycin," commented Walter Klemp, Chairman and CEO of Mole…n.
Development agreement made for new cancer treatment drugwww.manufacturingchemist.com › news › article_page › Development_agr...
www.manufacturingchemist.com
Jun 11, · ... breakthrough discovery, is now advancing to the stage of formulation development,” commented Walter Klemp, Mole…n's Chairman and CEO.
sorted by relevance / date